For example, the carriage of the PNPLA3 I148M variant is associated with a reduced beneficial effect of the exposure to dapaglifozin, an inhibitor of a sodium-glucose cotransporter-2 (SGLT2), against steatosis, while also with increased hepatic fat accumulation and liver damage associated with the administration of long-acting basal insulin [84,85,86]. Here, INS is linked to steatosis.